Introduction

Knee osteoarthritis is a common condition that causes pain, stiffness, and limits movement, often affecting daily life and wellbeing. Finding effective ways to manage symptoms is vital to maintaining independence and comfort. Arthrosamid is a relatively new injectable treatment designed to help relieve knee pain caused by osteoarthritis. This article will explain who is likely to benefit from Arthrosamid in the UK, highlight the differences between NHS and private access, and outline practical steps to explore whether this treatment could be right for you.

What Is Arthrosamid and How Does It Work?

Arthrosamid is an injectable gel made from polyacrylamide hydrogel, developed specifically to treat knee osteoarthritis. It works by cushioning the joint and supporting the tissue around it, potentially easing pain and improving function. While it isn’t a cure, research shows it to be both safe and effective in reducing symptoms.

A recent review explains, “PAAG hydrogel is a novel compound that has recently become available in the UK market under the name Arthrosamid to treat osteoarthritis (OA). It adheres to and bulks up the synovial membrane and acts as a scaffold to treat the synovium.” Moreover, a three-year clinical study found that Arthrosamid “fulfils an unmet clinical need for an effective, long-acting and safe non-surgical treatment that may postpone knee surgery for those with OA.”

Administration is performed by trained specialists in a clinical setting, ensuring your treatment and recovery are carefully managed. Experts such as Professor Paul Lee and the MSK Doctors team have extensive experience in musculoskeletal medicine, offering personalised care throughout this process.

Who Is Typically Eligible for Arthrosamid?

Determining if Arthrosamid is suitable involves assessing several key factors to ensure safe and effective treatment.

Typically, suitable candidates are those who:

• Have a diagnosis of moderate knee osteoarthritis confirmed by clinical assessment
• Continue to experience pain despite trying painkillers and physiotherapy
• Are otherwise in good health, aside from their knee condition

In contrast, Arthrosamid is not recommended for patients who:

• Are allergic to any ingredients in the gel
• Have an active infection in or around the knee
• Have certain other health issues that may raise treatment risks
• Have recently undergone knee surgery or require healing time

This helps you understand if you might fit the usual criteria, but a thorough review by professionals such as Professor Paul Lee and the MSK Doctors team remains essential to provide a clear, personalised recommendation.

NHS Pathway vs. Private Care: Accessing Arthrosamid in the UK

In the UK, accessing Arthrosamid can vary depending on whether you go through the NHS or private healthcare. While some NHS trusts offer this treatment, availability is limited, and patients must usually begin with a GP referral for specialist assessment — a process that can take time depending on local services.

Private healthcare often provides quicker access, with fewer restrictions, which appeals to many patients seeking a more flexible approach.

If you are considering Arthrosamid, it’s best to speak openly with your GP and explore advice from specialists like Professor Paul Lee or the MSK Doctors team, who understand both NHS and private routes and can guide you through the best options for your situation.

Frequently Asked Questions About Arthrosamid Eligibility

• Is there an age limit for Arthrosamid?
  No strict age limits apply. Suitability depends more on your overall health and knee condition.
• Can other health conditions affect my eligibility?
  Yes. Some medical issues may mean Arthrosamid isn’t suitable, so a full medical review is needed.
• Does having previous knee surgery matter?
  It might. Recent or complex surgeries mean your suitability will need careful evaluation.
• Is Arthrosamid suitable for mild symptoms?
  Typically, it is recommended for moderate symptoms unrelieved by other treatments.

Safety is a key consideration. Reviews confirm that “injection of PAAG hydrogel intraarticularly into the knee has been shown to be safe with no long-lasting adverse events reported.” Long-term evidence also supports its use: “Single injections of 6 ml intra-articular iPAAG are well tolerated and continue to provide clinically relevant and statistically significant effectiveness at 3 years after treatment.” Another study adds that iPAAG "offers comparable short-term efficacy and modest advantage at 6 months. However, long-term superiority is limited. It may be a complementary option in individualised osteoarthritis management.”

These points provide helpful guidance, but a personalised consultation with a qualified professional is the best way to determine if Arthrosamid is right for you.

What to Do Next: Steps Towards Assessment and Treatment

If you think Arthrosamid might be suitable, start by booking an appointment with your GP to discuss your symptoms and ask about referral options. If you prefer to seek private care, you can book a consultation with specialists such as Professor Paul Lee or the MSK Doctors team directly.

Ahead of your appointment, gather any previous medical reports, scans, or notes about your knee condition. This will help experts make a full assessment.

A thorough evaluation not only confirms eligibility but helps craft a treatment plan tailored to your individual needs. Research shows that “this PAAG hydrogel seems to be an efficacious and safe treatment option for knee OA and provides positive results for at least 2 years.” Additionally, longer-term follow-ups found “statistically significant decreases from baseline to 3 years for each of the 3 WOMAC subscale scores and the PGA,” highlighting sustained benefit.

Conclusion

Deciding if Arthrosamid is right for you involves considering a combination of clinical factors and personal health. Expert assessment — especially by well-regarded teams like those at MSK Doctors and specialists such as Professor Paul Lee — is invaluable for making the best choice with confidence. Use the information here as a starting point to take control of your knee health and explore treatments that could improve your quality of life.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A systematic review of the novel compound Arthrosamid polyacrylamide (PAAG) hydrogel for treatment of knee osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine, 104(15), e44655. https://doi.org/10.1097/MD.0000000000044655
• Bliddal, H., Beier, J., Hartkopp, A., Conaghan, P., & Henriksen, M. (2023). Polyacrylamide hydrogel for the treatment of knee osteoarthritis: 3 year follow up results of a prospective clinical study. Annals of the Rheumatic Diseases, 82(Suppl 1), 2041. https://doi.org/10.1136/annrheumdis-2023-eular.6038